Prostate Cancer Screening: 10 Myths Every Man Should Know
Prostate cancer screening can sound simple: have a PSA blood test, receive a result, and find out whether something is wrong. In reality, the decision is more complicated. A man can feel completely healthy and still have prostate cancer, while an elevated PSA does not automatically mean that cancer is present.
A conversation with a qualified healthcare professional can help men understand their individual prostate cancer risk and screening options.
What is prostate cancer screening?
Prostate cancer screening involves checking men who do not have symptoms for signs that prostate cancer may be present. The main screening test is a blood test that measures prostate-specific antigen (PSA). Because PSA can rise for reasons other than cancer, an abnormal result does not diagnose prostate cancer by itself. Screening decisions should consider age, family history, ancestry, genetic risk, overall health, life expectancy and personal preferences.
Key point: PSA screening is not a simple pass-or-fail cancer test. The most appropriate screening strategy depends on a man’s individual risk and what he would want to do if an abnormal result requires further investigation.
Why Prostate Cancer Screening Is Complicated
Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. According to the International Agency for Research on Cancer (IARC), more than 1.5 million prostate cancer cases were diagnosed globally in 2024, and almost 420,000 people died from the disease.
However, prostate cancer is not a single type of disease with a single pattern of behavior. Some tumors grow slowly and may never cause symptoms or shorten a person’s life, while others can grow aggressively and spread beyond the prostate.
This difference creates an important challenge for screening. The goal is not simply to discover every possible prostate abnormality. The goal is to identify cancers that are clinically important while reducing unnecessary investigations and treatment.
Modern approaches therefore emphasize informed decision-making, individual risk assessment and appropriate follow-up rather than automatically screening every man in exactly the same way.
10 Prostate Cancer Screening Myths and Facts
Myth #1: Only Very Old Men Need to Think About Prostate Cancer Screening
Prostate cancer becomes more common as men age, but age is not the only factor that affects risk.
Family history, ancestry and inherited genetic factors can influence the likelihood of developing prostate cancer. Men with a father or brother who developed prostate cancer, particularly at a younger age, may need to discuss screening earlier than men at average risk.
The American Cancer Society recommends that men at average risk begin a screening discussion around age 50 if they are expected to live at least another 10 years. It recommends discussion from age 45 for men at higher risk, including African American men and men with a father or brother diagnosed with prostate cancer before age 65. Men with more than one first-degree relative diagnosed early should discuss screening from age 40.
The American Urological Association/Society of Urologic Oncology also emphasizes individualized risk assessment, including factors such as Black ancestry, strong family history and inherited genetic mutations.
Bottom line: Do not use age alone to determine whether prostate cancer screening is worth discussing.
Myth #2: Prostate Cancer Screening Is Always Painful
The PSA test itself is a blood test. A healthcare professional takes a blood sample and the laboratory measures the amount of prostate-specific antigen in the blood.
A digital rectal examination, or DRE, is a separate procedure. During a DRE, a clinician uses a gloved and lubricated finger to examine the prostate through the rectum. Whether it is useful depends on the clinical situation and the healthcare professional’s assessment.
Not every discussion about PSA screening automatically means that a DRE will be performed.
Bottom line: Ask what tests are being recommended and why. PSA testing and DRE are not the same procedure.
Myth #3: If You Have No Symptoms, You Cannot Have Prostate Cancer
Early prostate cancer frequently causes no noticeable symptoms. This is one reason screening and diagnostic evaluation need to be distinguished.
Urinary symptoms such as a weak urine stream, difficulty starting urination or frequent nighttime urination can occur with benign prostate enlargement and other conditions. They can also occur in some men with prostate cancer, but symptoms alone cannot determine the cause.
Screening is generally intended for people without symptoms. If a man develops persistent or unexplained symptoms, he should seek medical assessment rather than waiting for his next routine screening appointment.
Bottom line: Feeling well does not prove that prostate cancer is absent.
Myth #4: A PSA Test Can Tell You With Certainty Whether You Have Prostate Cancer
PSA is useful, but it is not a definitive cancer test.
PSA can increase because of prostate cancer, but it can also rise with benign prostate enlargement, inflammation and other prostate-related conditions. Some men with prostate cancer can also have PSA levels that are not dramatically elevated.
The American Cancer Society states that there is no single PSA cutoff that can determine with certainty whether a man does or does not have prostate cancer.
This means that an elevated PSA should generally be interpreted in context. Depending on the circumstances, a healthcare professional may repeat the test, consider other tests, use a validated risk assessment tool, request prostate MRI or refer the patient to a urologist.
Bottom line: Think of PSA as a risk signal, not a cancer verdict.
Myth #5: Family History Does Not Matter If You Feel Healthy
Family history can affect prostate cancer risk regardless of how healthy a man feels.
A father or brother with prostate cancer can increase risk, particularly when the relative was diagnosed at a younger age. Risk assessment can become even more important when several close relatives have had prostate cancer or other cancers associated with inherited cancer-risk mutations.
When possible, men should find out which relatives were affected, what type of cancer they had and approximately how old they were when diagnosed.
Bottom line: Tell your healthcare professional about prostate cancer in close relatives, even if you have no symptoms.
Myth #6: PSA Screening Causes Prostate Cancer
A PSA blood test does not cause prostate cancer.
However, an abnormal screening result can sometimes lead to additional testing, including prostate biopsy. A biopsy is a diagnostic procedure rather than a screening test, and it carries potential risks such as bleeding, infection and discomfort.
This is one reason shared decision-making is important. Before having a PSA test, a man should understand that an abnormal result may lead to repeat testing, imaging, specialist assessment or biopsy.
Bottom line: The PSA test does not cause cancer, but screening can lead to additional investigations that have their own risks.
Myth #7: Every Prostate Cancer Is Aggressive
Prostate cancers differ substantially in their biological behavior.
Some cancers grow slowly and may remain confined to the prostate for many years. Others have characteristics associated with faster growth or spread.
This is why doctors consider factors such as cancer grade, stage, PSA level, imaging findings and other clinical information before recommending treatment.
For selected men with lower-risk prostate cancer, active surveillance may be appropriate. Active surveillance involves regular monitoring rather than immediate treatment.
Bottom line: A prostate cancer diagnosis does not automatically mean that the disease is aggressive or that immediate treatment is required.
Myth #8: A Healthy Lifestyle Eliminates the Need to Think About Prostate Cancer
Regular physical activity, a healthy diet, maintaining a healthy weight and avoiding tobacco are important for overall health. However, healthy habits do not eliminate prostate cancer risk.
Age, family history, ancestry and inherited genetic factors can influence risk independently of lifestyle.
Healthy living and cancer screening serve different purposes. Lifestyle measures support general health, while screening is intended to identify possible disease before symptoms develop.
Bottom line: Continue healthy habits, but do not assume that they completely remove the need for individualized cancer-risk assessment.
Myth #9: Prostate Cancer Screening Always Leads to Unnecessary Treatment
Screening can sometimes detect prostate cancers that would never have caused symptoms or affected a man’s lifespan. This is known as overdiagnosis.
Overdiagnosis matters because a cancer diagnosis can lead to anxiety, additional investigations and treatment. Surgery and radiation can be appropriate and potentially lifesaving for some men, but they can also cause side effects, including urinary, sexual or bowel problems.
Modern prostate cancer management therefore does not assume that every detected cancer requires immediate treatment.
For appropriately selected men, active surveillance can provide an alternative to immediate treatment while the cancer is monitored carefully.
Bottom line: Screening and treatment are separate decisions. Finding prostate cancer does not automatically mean immediate surgery or radiation.
Myth #10: Prostate Cancer Is an Inevitable Part of Aging
Age is one of the strongest risk factors for prostate cancer, but aging does not mean that every man will develop clinically significant prostate cancer.
Some prostate tumors grow slowly and may never cause serious health problems. This is one reason that overall health and life expectancy are important when deciding whether screening is likely to provide meaningful benefit.
The American Cancer Society advises that men with a life expectancy of less than 10 years generally should not be offered prostate cancer screening because they are unlikely to benefit from detecting a slow-growing cancer.
Bottom line: Age increases risk, but prostate cancer is not an inevitable consequence of getting older.
Who Should Discuss Prostate Cancer Screening?
There is no single screening schedule that is appropriate for every man. The decision depends on personal risk and on the potential benefits and harms of finding prostate cancer.
- Average-risk men: The American Cancer Society recommends discussing screening around age 50 for men expected to live at least another 10 years.
- Higher-risk men: Men with African ancestry or a father or brother diagnosed with prostate cancer before age 65 may need an earlier discussion.
- Very high-risk men: Men with more than one first-degree relative diagnosed with prostate cancer at an early age may need to begin discussing screening around age 40.
- Genetic risk: Certain inherited mutations, including BRCA-related mutations, can influence prostate cancer risk.
- Previous abnormal PSA: Men with previous PSA abnormalities may require individualized follow-up.
- Symptoms: Men with persistent or unexplained symptoms require medical assessment rather than simply waiting for routine screening.
Understanding the PSA Test
PSA stands for prostate-specific antigen. It is a protein produced by cells in the prostate and can be measured through a blood test.
PSA levels tend to increase as the likelihood of prostate cancer increases, but the relationship is not absolute. There is no single PSA number that can completely rule prostate cancer in or out.
The American Cancer Society notes that some clinicians use a PSA level of 4 ng/mL as a threshold for considering further evaluation, while others may use lower or age-specific thresholds. The appropriate interpretation depends on the individual clinical situation.
A PSA result should therefore be considered alongside factors such as age, prostate size, family history, previous PSA measurements and other risk factors.
Important: Do not diagnose yourself from a PSA result found on a laboratory report or online calculator. A healthcare professional should interpret the result in its clinical context.
What Can Cause an Elevated PSA?
Prostate cancer is one possible cause of an elevated PSA, but it is not the only one.
- Benign prostate enlargement
- Inflammation of the prostate
- Some prostate or urinary conditions
- Recent prostate-related procedures
- Other factors considered by the treating clinician
For this reason, an elevated PSA does not automatically mean that a man has cancer.
Depending on the circumstances, a healthcare professional may recommend repeating the PSA test, reviewing possible temporary causes, using additional risk assessment, ordering imaging or referring the patient to a urologist.
What Happens After an Abnormal PSA?
An abnormal PSA is usually the beginning of an evaluation rather than the end of one.
The next step depends on the man’s overall risk, the PSA result, previous PSA measurements and other clinical findings.
Possible next steps include:
- Repeating the PSA test when clinically appropriate
- Reviewing family and medical history
- Performing a clinical prostate assessment
- Using a validated prostate cancer risk calculator
- Considering additional biomarkers in selected situations
- Ordering prostate MRI when appropriate
- Referral to a urologist
- Considering biopsy when the overall evidence supports tissue diagnosis
The American Urological Association/Society of Urologic Oncology emphasizes risk assessment and shared decision-making when evaluating men for clinically significant prostate cancer.
Where Does MRI Fit Into Prostate Cancer Evaluation?
Multiparametric MRI has become an important tool in the evaluation of some men with suspected prostate cancer.
MRI can provide detailed images of the prostate and may help identify areas that require further investigation. In selected patients, MRI findings can help guide biopsy decisions.
However, MRI is not a universal screening test for every healthy man, and its usefulness depends on the patient’s clinical situation, the quality of the imaging and the expertise available to interpret it.
The broader goal of modern risk-stratified evaluation is to improve detection of clinically important cancers while reducing unnecessary biopsies and diagnosis of cancers that may never have caused harm.
What Is Active Surveillance?
Active surveillance is a management strategy used for selected men whose prostate cancer has features suggesting a lower risk of progression.
Instead of immediately undergoing surgery or radiation, the patient is monitored using an agreed follow-up plan. This can include PSA testing, clinical assessments, imaging and, when appropriate, repeat biopsy.
If monitoring shows evidence that the cancer is becoming more clinically significant, treatment can then be considered.
Active surveillance should not be confused with ignoring cancer. It is a structured medical management strategy designed to avoid unnecessary treatment in men who may safely be monitored.
Prostate Cancer Screening in Kenya
For Kenyan men, local guidance is important because healthcare systems differ in resources, screening practices and access to diagnostic services.
Kenya’s National Cancer Screening and Early Diagnosis Guidelines, Second Edition, 2024, identify prostate cancer as a major cancer burden in the country. The guideline describes prostate cancer screening as a targeted approach and recommends PSA-based screening using an individualized approach, with shared decision-making offered to eligible men.
This means that a Kenyan man should not assume that every man needs exactly the same PSA testing schedule. Age, personal risk, family history, previous results and the availability of appropriate follow-up all matter.
The Kenyan guideline is particularly relevant when considering prostate cancer in men of African ancestry, who are recognized as having increased risk in several international guidelines.
If a PSA result is abnormal, it is important to have access to appropriate clinical evaluation rather than treating the laboratory result as a diagnosis.
Screening Is Different From Diagnosis
One of the most important distinctions in prostate health is the difference between screening and diagnosis.
Screening is performed in people who do not have symptoms to identify those who may have a higher likelihood of disease.
Diagnosis involves investigating an abnormal screening result or symptoms to determine whether a disease is actually present.
Treatment is the management of a confirmed disease based on its characteristics and the patient’s circumstances.
A PSA test is therefore not the same thing as a prostate cancer diagnosis. When cancer is suspected, further assessment may be necessary, and a biopsy can be used to establish the presence of cancer in prostate tissue.
Screening Does Not Replace Evaluation of Symptoms
Men should not wait for a routine screening appointment if they develop concerning symptoms.
Symptoms that deserve medical evaluation can include persistent difficulty urinating, a weak urinary stream, blood in the urine or semen, unexplained pelvic discomfort, or persistent back or bone pain.
These symptoms do not automatically mean prostate cancer. Benign prostate enlargement, urinary infection and other conditions can cause similar symptoms. A healthcare professional can determine what evaluation is appropriate.
Questions to Ask Before Having a PSA Test
A useful screening discussion should involve more than simply requesting a blood test.
- What is my personal risk of prostate cancer?
- Does my family history change when I should consider screening?
- Does my ancestry affect my risk?
- What are the potential benefits of PSA screening for me?
- What are the possible harms or limitations?
- What would happen if my PSA result were elevated?
- Would the result need to be repeated?
- Would I need additional testing or a urology referral?
- How frequently should I be reassessed if my result is reassuring?
Understanding the possible next steps before testing can make the screening decision more informed.
How Screening Can Lead to Both Benefits and Harms
Screening has potential benefits. Detecting a clinically important prostate cancer earlier may provide an opportunity for treatment before the cancer spreads.
However, screening also has limitations. Some men may receive abnormal results that do not ultimately indicate cancer. Others may undergo additional investigations or biopsies. Screening can also detect slow-growing cancers that might never have caused symptoms during the person’s lifetime.
IARC identifies overdiagnosis as an important concern in prostate cancer screening and has highlighted risk-stratified approaches that combine PSA testing with individual risk assessment and, where appropriate, MRI-guided biopsy decisions.
The purpose of informed screening is therefore not simply to maximize the number of cancers detected. It is to make a decision in which the potential benefits are considered alongside the possible harms.
Related Men’s Health Resources
For more information about men’s health, you can also explore these related VitalWell Hub resources:
These articles provide general men’s health information and should not be used as substitutes for prostate cancer screening, diagnosis or individualized medical advice.
Frequently Asked Questions
What is prostate cancer screening?
Prostate cancer screening involves checking men without symptoms for signs that prostate cancer may be present. PSA testing is the main screening test. A DRE may also be considered depending on the clinical situation.
At what age should men discuss prostate cancer screening?
The appropriate age depends on individual risk. The American Cancer Society recommends discussion around age 50 for men at average risk who are expected to live at least another 10 years, around age 45 for men at higher risk, and around age 40 for men with particularly high-risk family histories.
Does a high PSA mean that I have prostate cancer?
No. PSA can increase for several reasons, including benign prostate enlargement and inflammation. An elevated PSA requires clinical interpretation and may lead to repeat testing or further evaluation.
Can prostate cancer occur without symptoms?
Yes. Early prostate cancer frequently causes no noticeable symptoms. This is why screening and diagnostic evaluation should be considered separately.
Does prostate cancer always require immediate treatment?
No. Selected men with lower-risk prostate cancer may be candidates for active surveillance rather than immediate treatment. The appropriate management depends on the characteristics of the cancer and the person’s overall circumstances.
Should Kenyan men discuss PSA testing with a healthcare professional?
Yes. Kenya’s 2024 National Cancer Screening and Early Diagnosis Guidelines support an individualized PSA-based approach and shared decision-making for eligible men.
Can a normal PSA completely rule out prostate cancer?
No. PSA can provide useful information about risk, but there is no single PSA level that completely rules out prostate cancer.
What should I do if my PSA is elevated?
Do not assume that an elevated PSA means you have cancer. Discuss the result with a healthcare professional. Depending on the circumstances, repeat testing, additional risk assessment, MRI or urology referral may be considered.
Conclusion
Prostate cancer screening is not simply a matter of deciding whether a PSA number is high or low. The decision involves understanding personal risk, the limitations of PSA testing, the possibility of false-positive results, the potential for overdiagnosis and the options available if cancer is detected.
Age, family history, ancestry, inherited genetic factors, previous PSA results, overall health and life expectancy can all influence the decision.
For some men, screening may provide an opportunity to identify clinically important cancer earlier. For others, the potential harms of screening may outweigh the likely benefits. This is why major medical organizations emphasize informed and individualized decision-making.
If you are in your 40s or older, particularly if you have a close family history of prostate cancer, African ancestry or another recognized risk factor, discuss your individual risk with a qualified healthcare professional.
The goal is not simply to find cancer. The goal is to make a well-informed decision about prostate health while understanding both the potential benefits and limitations of screening.
Medical disclaimer: This article is for general health education only. It does not provide a diagnosis or replace individualized medical advice, examination or treatment. If you have persistent symptoms, an abnormal PSA result or concerns about your prostate cancer risk, consult a qualified healthcare professional.
References and Medical Sources
-
American Cancer Society.
American Cancer Society Recommendations for Prostate Cancer Early Detection.
https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/acs-recommendations.html -
American Cancer Society.
Prostate Cancer Screening Tests.
https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/tests.html -
American Urological Association/Society of Urologic Oncology.
Early Detection of Prostate Cancer: AUA/SUO Guideline, 2023.
American Urological Association prostate cancer early detection guideline -
International Agency for Research on Cancer (IARC), World Health Organization.
Prostate Cancer.
https://www.iarc.who.int/cancer-type/prostate-cancer/ -
World Health Organization Regional Office for Africa / Ministry of Health Kenya.
National Cancer Screening and Early Diagnosis Guidelines, Second Edition, 2024.
Kenya National Cancer Screening and Early Diagnosis Guidelines 2024
Sources reviewed: The recommendations and factual information in this article were checked against the above professional and public-health sources. Screening recommendations can change as evidence develops, so readers should confirm current advice with a qualified healthcare professional.